| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 86 | 2025 | 977 | 10.750 |
Why?
|
| Mammography | 26 | 2024 | 168 | 4.390 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2023 | 244 | 3.530 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 12 | 2020 | 42 | 3.300 |
Why?
|
| Neoplasms | 17 | 2023 | 448 | 2.820 |
Why?
|
| Humans | 179 | 2025 | 17376 | 2.780 |
Why?
|
| Middle Aged | 127 | 2025 | 7885 | 2.780 |
Why?
|
| Breast | 16 | 2023 | 84 | 2.730 |
Why?
|
| Female | 143 | 2025 | 12444 | 2.650 |
Why?
|
| Prostatic Neoplasms | 15 | 2020 | 263 | 2.630 |
Why?
|
| Breast Density | 8 | 2024 | 31 | 2.590 |
Why?
|
| Aged | 93 | 2025 | 6129 | 2.130 |
Why?
|
| Adult | 93 | 2025 | 7529 | 2.080 |
Why?
|
| Hypoglycemic Agents | 10 | 2015 | 251 | 1.930 |
Why?
|
| Risk Factors | 64 | 2024 | 3255 | 1.890 |
Why?
|
| Carcinoma, Ductal, Breast | 10 | 2020 | 52 | 1.830 |
Why?
|
| Biomarkers, Tumor | 11 | 2021 | 145 | 1.820 |
Why?
|
| Case-Control Studies | 42 | 2023 | 1100 | 1.740 |
Why?
|
| Cohort Studies | 50 | 2023 | 2526 | 1.730 |
Why?
|
| California | 45 | 2025 | 2317 | 1.600 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2015 | 666 | 1.490 |
Why?
|
| Receptor, ErbB-2 | 8 | 2023 | 47 | 1.480 |
Why?
|
| Thiazolidinediones | 7 | 2015 | 50 | 1.440 |
Why?
|
| Antineoplastic Agents, Hormonal | 8 | 2025 | 65 | 1.400 |
Why?
|
| Aged, 80 and over | 36 | 2025 | 1942 | 1.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2017 | 165 | 1.320 |
Why?
|
| Pancreatic Neoplasms | 3 | 2023 | 69 | 1.290 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2025 | 372 | 1.270 |
Why?
|
| Male | 68 | 2025 | 9843 | 1.250 |
Why?
|
| Adenocarcinoma | 9 | 2023 | 173 | 1.240 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 270 | 1.180 |
Why?
|
| Colorectal Neoplasms | 6 | 2017 | 627 | 1.170 |
Why?
|
| Antihypertensive Agents | 5 | 2020 | 155 | 1.160 |
Why?
|
| Women's Health | 12 | 2022 | 197 | 1.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2016 | 53 | 1.100 |
Why?
|
| Registries | 19 | 2020 | 460 | 1.070 |
Why?
|
| Risk | 19 | 2020 | 498 | 1.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 5 | 2011 | 64 | 1.030 |
Why?
|
| Risk Assessment | 19 | 2020 | 1079 | 1.000 |
Why?
|
| Proportional Hazards Models | 22 | 2022 | 702 | 0.990 |
Why?
|
| Mastectomy, Segmental | 6 | 2020 | 21 | 0.990 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 42 | 0.950 |
Why?
|
| Retrospective Studies | 22 | 2025 | 2428 | 0.930 |
Why?
|
| Follow-Up Studies | 27 | 2017 | 1155 | 0.920 |
Why?
|
| Carcinoma | 2 | 2015 | 22 | 0.900 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2009 | 109 | 0.880 |
Why?
|
| Incidence | 23 | 2016 | 1266 | 0.870 |
Why?
|
| Neoplasm Staging | 18 | 2025 | 341 | 0.860 |
Why?
|
| Smoking | 10 | 2015 | 428 | 0.850 |
Why?
|
| European Continental Ancestry Group | 11 | 2020 | 480 | 0.830 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2015 | 58 | 0.830 |
Why?
|
| Prognosis | 19 | 2023 | 604 | 0.820 |
Why?
|
| Menarche | 3 | 2024 | 28 | 0.780 |
Why?
|
| Drug Prescriptions | 4 | 2016 | 148 | 0.770 |
Why?
|
| Central Nervous System Stimulants | 4 | 2011 | 26 | 0.770 |
Why?
|
| Herpes Zoster | 2 | 2014 | 82 | 0.760 |
Why?
|
| Carcinoma in Situ | 5 | 2009 | 17 | 0.740 |
Why?
|
| Adiposity | 2 | 2024 | 67 | 0.740 |
Why?
|
| Continental Population Groups | 9 | 2017 | 289 | 0.700 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 31 | 0.690 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2025 | 363 | 0.670 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2013 | 118 | 0.660 |
Why?
|
| Odds Ratio | 15 | 2017 | 644 | 0.650 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2015 | 51 | 0.630 |
Why?
|
| Menopause | 6 | 2011 | 68 | 0.630 |
Why?
|
| Neoplasm Invasiveness | 8 | 2017 | 80 | 0.620 |
Why?
|
| Body Mass Index | 14 | 2015 | 937 | 0.600 |
Why?
|
| Fractures, Bone | 1 | 2019 | 94 | 0.590 |
Why?
|
| Genome-Wide Association Study | 10 | 2025 | 248 | 0.590 |
Why?
|
| Mammary Glands, Human | 3 | 2015 | 8 | 0.570 |
Why?
|
| Alaska Natives | 1 | 2017 | 5 | 0.570 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 142 | 0.570 |
Why?
|
| Adolescent | 22 | 2024 | 3533 | 0.570 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 27 | 0.570 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2025 | 18 | 0.560 |
Why?
|
| Indians, North American | 1 | 2017 | 49 | 0.560 |
Why?
|
| Managed Care Programs | 2 | 2010 | 309 | 0.560 |
Why?
|
| Paroxetine | 2 | 2015 | 14 | 0.550 |
Why?
|
| Receptors, Estrogen | 7 | 2025 | 53 | 0.550 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2015 | 19 | 0.550 |
Why?
|
| Young Adult | 16 | 2024 | 2473 | 0.550 |
Why?
|
| Cost of Illness | 2 | 2009 | 93 | 0.540 |
Why?
|
| Metformin | 3 | 2015 | 50 | 0.540 |
Why?
|
| Gallbladder | 1 | 2017 | 1 | 0.540 |
Why?
|
| Lip Neoplasms | 2 | 2017 | 2 | 0.540 |
Why?
|
| Drug Utilization Review | 2 | 2007 | 24 | 0.540 |
Why?
|
| Hydrochlorothiazide | 2 | 2017 | 4 | 0.540 |
Why?
|
| Cholinergic Antagonists | 1 | 2017 | 7 | 0.530 |
Why?
|
| Legislation, Medical | 1 | 2016 | 5 | 0.530 |
Why?
|
| Logistic Models | 15 | 2021 | 884 | 0.530 |
Why?
|
| Disclosure | 1 | 2016 | 15 | 0.530 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 16 | 0.530 |
Why?
|
| Child Health Services | 2 | 2009 | 106 | 0.520 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2016 | 4 | 0.520 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 4 | 0.520 |
Why?
|
| Hypercholesterolemia | 1 | 2016 | 24 | 0.510 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2017 | 311 | 0.510 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 18 | 0.510 |
Why?
|
| Pharmacoepidemiology | 3 | 2023 | 18 | 0.510 |
Why?
|
| Melanoma | 1 | 2016 | 35 | 0.510 |
Why?
|
| Time Factors | 13 | 2023 | 1044 | 0.500 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 102 | 0.500 |
Why?
|
| United States | 17 | 2019 | 3891 | 0.480 |
Why?
|
| Benzodiazepines | 2 | 2015 | 28 | 0.480 |
Why?
|
| Anti-Bacterial Agents | 2 | 2007 | 144 | 0.470 |
Why?
|
| Body Constitution | 3 | 2007 | 39 | 0.470 |
Why?
|
| Gene Expression Profiling | 5 | 2023 | 35 | 0.470 |
Why?
|
| Receptors, Progesterone | 7 | 2023 | 50 | 0.460 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 58 | 0.460 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2025 | 77 | 0.450 |
Why?
|
| Confounding Factors (Epidemiology) | 6 | 2016 | 84 | 0.450 |
Why?
|
| Neuralgia | 1 | 2014 | 3 | 0.450 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 58 | 0.440 |
Why?
|
| Exercise | 4 | 2016 | 513 | 0.440 |
Why?
|
| Ethnic Groups | 8 | 2017 | 456 | 0.440 |
Why?
|
| Peritoneal Neoplasms | 1 | 2014 | 2 | 0.440 |
Why?
|
| Ovariectomy | 1 | 2014 | 9 | 0.440 |
Why?
|
| Fluoxetine | 1 | 2013 | 17 | 0.430 |
Why?
|
| Testicular Neoplasms | 1 | 2013 | 11 | 0.430 |
Why?
|
| Barrett Esophagus | 7 | 2008 | 114 | 0.430 |
Why?
|
| Hysterectomy | 1 | 2014 | 29 | 0.430 |
Why?
|
| Carcinoma, Ductal | 2 | 2011 | 4 | 0.430 |
Why?
|
| Insulin, Long-Acting | 1 | 2013 | 11 | 0.430 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2013 | 46 | 0.420 |
Why?
|
| Gonadal Steroid Hormones | 4 | 2017 | 27 | 0.420 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 52 | 0.410 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 4 | 0.410 |
Why?
|
| Mass Screening | 3 | 2016 | 671 | 0.410 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 533 | 0.410 |
Why?
|
| Lymph Nodes | 1 | 2013 | 17 | 0.410 |
Why?
|
| Nifedipine | 1 | 2012 | 7 | 0.400 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 20 | 0.400 |
Why?
|
| Stomach Neoplasms | 3 | 2002 | 42 | 0.400 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2024 | 26 | 0.400 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 44 | 0.390 |
Why?
|
| Tamoxifen | 4 | 2016 | 56 | 0.380 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 74 | 0.380 |
Why?
|
| Reproductive History | 2 | 2011 | 17 | 0.380 |
Why?
|
| Thyroxine | 1 | 2011 | 7 | 0.380 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 15 | 0.370 |
Why?
|
| Alcoholism | 1 | 2015 | 337 | 0.360 |
Why?
|
| Breast Neoplasms, Male | 3 | 2015 | 10 | 0.360 |
Why?
|
| Norepinephrine | 1 | 2011 | 2 | 0.360 |
Why?
|
| Colonic Neoplasms | 2 | 2011 | 163 | 0.350 |
Why?
|
| Breast Diseases | 2 | 2008 | 18 | 0.350 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 65 | 0.350 |
Why?
|
| Longitudinal Studies | 6 | 2015 | 677 | 0.340 |
Why?
|
| Carcinoma, Lobular | 3 | 2012 | 10 | 0.340 |
Why?
|
| Helicobacter Infections | 3 | 2008 | 22 | 0.340 |
Why?
|
| Helicobacter pylori | 3 | 2008 | 24 | 0.340 |
Why?
|
| Medication Adherence | 2 | 2025 | 239 | 0.330 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 4 | 0.330 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 114 | 0.330 |
Why?
|
| Physical Fitness | 1 | 2010 | 70 | 0.330 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2010 | 33 | 0.330 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 11 | 0.330 |
Why?
|
| SEER Program | 5 | 2016 | 94 | 0.320 |
Why?
|
| Mutation | 3 | 2023 | 132 | 0.310 |
Why?
|
| Age Distribution | 6 | 2012 | 239 | 0.310 |
Why?
|
| Transcriptome | 3 | 2025 | 25 | 0.310 |
Why?
|
| Maternal Welfare | 1 | 2009 | 12 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2014 | 27 | 0.310 |
Why?
|
| Colonoscopy | 2 | 2008 | 257 | 0.310 |
Why?
|
| Precancerous Conditions | 3 | 2008 | 48 | 0.310 |
Why?
|
| Asian Continental Ancestry Group | 5 | 2017 | 87 | 0.300 |
Why?
|
| Disabled Children | 1 | 2009 | 28 | 0.300 |
Why?
|
| Early Detection of Cancer | 5 | 2023 | 529 | 0.300 |
Why?
|
| Hypertension | 3 | 2020 | 469 | 0.290 |
Why?
|
| Treatment Outcome | 7 | 2020 | 1170 | 0.290 |
Why?
|
| Methylphenidate | 1 | 2007 | 3 | 0.290 |
Why?
|
| Sentinel Surveillance | 1 | 2007 | 12 | 0.290 |
Why?
|
| Mothers | 1 | 2009 | 103 | 0.280 |
Why?
|
| Colonic Polyps | 1 | 2007 | 36 | 0.280 |
Why?
|
| Dairy Products | 1 | 2007 | 23 | 0.270 |
Why?
|
| Child | 8 | 2024 | 2382 | 0.270 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2007 | 64 | 0.270 |
Why?
|
| Cholesterol | 2 | 2017 | 82 | 0.270 |
Why?
|
| Mental Health Services | 1 | 2009 | 154 | 0.270 |
Why?
|
| Health Care Costs | 1 | 2009 | 211 | 0.270 |
Why?
|
| Pathology, Clinical | 2 | 2010 | 14 | 0.260 |
Why?
|
| Aspirin | 2 | 2007 | 63 | 0.250 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2006 | 11 | 0.250 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2006 | 12 | 0.250 |
Why?
|
| Estrogen Replacement Therapy | 5 | 2008 | 100 | 0.250 |
Why?
|
| Blood Glucose | 1 | 2008 | 315 | 0.250 |
Why?
|
| Antibodies, Viral | 3 | 2024 | 66 | 0.250 |
Why?
|
| Alcohol Drinking | 4 | 2020 | 355 | 0.240 |
Why?
|
| Asthma | 1 | 2009 | 388 | 0.240 |
Why?
|
| Electronic Health Records | 5 | 2015 | 707 | 0.240 |
Why?
|
| Age Factors | 11 | 2016 | 884 | 0.240 |
Why?
|
| Condylomata Acuminata | 4 | 1998 | 23 | 0.240 |
Why?
|
| Denmark | 4 | 2020 | 17 | 0.240 |
Why?
|
| State Health Plans | 1 | 2005 | 33 | 0.230 |
Why?
|
| Recurrence | 6 | 2023 | 165 | 0.230 |
Why?
|
| Life Style | 5 | 2016 | 316 | 0.230 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 5 | 0.220 |
Why?
|
| Confidence Intervals | 6 | 2016 | 231 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 18 | 0.220 |
Why?
|
| Algorithms | 5 | 2023 | 226 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 120 | 0.220 |
Why?
|
| Diuretics | 2 | 2017 | 19 | 0.210 |
Why?
|
| Postmenopause | 5 | 2011 | 248 | 0.210 |
Why?
|
| Antigens, Bacterial | 2 | 2007 | 8 | 0.210 |
Why?
|
| Bacterial Proteins | 2 | 2007 | 13 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 21 | 0.210 |
Why?
|
| Socioeconomic Factors | 4 | 2020 | 609 | 0.200 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2022 | 2 | 0.200 |
Why?
|
| Prospective Studies | 10 | 2020 | 1229 | 0.200 |
Why?
|
| Surveys and Questionnaires | 7 | 2016 | 1287 | 0.200 |
Why?
|
| Prevalence | 5 | 2017 | 839 | 0.190 |
Why?
|
| Estrogen Receptor alpha | 4 | 2015 | 25 | 0.190 |
Why?
|
| Calcium Channel Blockers | 2 | 2020 | 15 | 0.190 |
Why?
|
| Genetic Testing | 3 | 2017 | 70 | 0.180 |
Why?
|
| Survival Rate | 3 | 2017 | 253 | 0.180 |
Why?
|
| African Americans | 4 | 2015 | 443 | 0.180 |
Why?
|
| Comorbidity | 2 | 2017 | 564 | 0.180 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 300 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 56 | 0.180 |
Why?
|
| Molecular Epidemiology | 1 | 2021 | 44 | 0.180 |
Why?
|
| Sexual Behavior | 3 | 1998 | 128 | 0.180 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 35 | 0.180 |
Why?
|
| Multifactorial Inheritance | 1 | 2020 | 21 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 10 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 15 | 0.170 |
Why?
|
| Carcinogenesis | 1 | 2020 | 9 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1287 | 0.170 |
Why?
|
| Data Collection | 2 | 2012 | 240 | 0.170 |
Why?
|
| Linear Models | 3 | 2011 | 210 | 0.170 |
Why?
|
| Premenopause | 4 | 2022 | 24 | 0.170 |
Why?
|
| Hair | 1 | 2000 | 7 | 0.170 |
Why?
|
| Face | 1 | 2000 | 5 | 0.170 |
Why?
|
| Gastroesophageal Reflux | 4 | 2008 | 77 | 0.170 |
Why?
|
| Depression | 2 | 2015 | 487 | 0.170 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 2 | 0.170 |
Why?
|
| Health Maintenance Organizations | 6 | 2009 | 408 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 538 | 0.170 |
Why?
|
| Child, Preschool | 4 | 2011 | 1375 | 0.170 |
Why?
|
| Prostate-Specific Antigen | 3 | 2017 | 76 | 0.160 |
Why?
|
| Tobacco Smoking | 1 | 2020 | 19 | 0.160 |
Why?
|
| Trastuzumab | 3 | 2014 | 19 | 0.160 |
Why?
|
| Heart Failure | 3 | 2016 | 404 | 0.160 |
Why?
|
| Anthropometry | 2 | 2017 | 60 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 35 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2017 | 537 | 0.160 |
Why?
|
| Protective Factors | 2 | 2016 | 32 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 367 | 0.160 |
Why?
|
| Barbiturates | 1 | 1999 | 1 | 0.160 |
Why?
|
| Abdominal Fat | 2 | 2011 | 13 | 0.160 |
Why?
|
| Immunoenzyme Techniques | 3 | 2014 | 22 | 0.160 |
Why?
|
| Behavior | 2 | 2017 | 17 | 0.160 |
Why?
|
| Accidental Falls | 1 | 2019 | 46 | 0.160 |
Why?
|
| RNA, Messenger | 3 | 2014 | 72 | 0.150 |
Why?
|
| Neoplasm Grading | 3 | 2014 | 49 | 0.150 |
Why?
|
| Esophageal Neoplasms | 5 | 2008 | 115 | 0.150 |
Why?
|
| Phenobarbital | 1 | 1998 | 2 | 0.150 |
Why?
|
| Drug Utilization | 2 | 2017 | 122 | 0.150 |
Why?
|
| Telemedicine | 1 | 2022 | 182 | 0.150 |
Why?
|
| Propensity Score | 1 | 2019 | 82 | 0.150 |
Why?
|
| Parity | 2 | 2010 | 57 | 0.150 |
Why?
|
| Aging | 1 | 2000 | 160 | 0.150 |
Why?
|
| Hypnotics and Sedatives | 1 | 1998 | 15 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 124 | 0.150 |
Why?
|
| Osteoporosis | 1 | 2019 | 77 | 0.150 |
Why?
|
| Genital Diseases, Female | 1 | 1998 | 9 | 0.150 |
Why?
|
| Biomarkers | 3 | 2015 | 306 | 0.150 |
Why?
|
| Organizations, Nonprofit | 2 | 2009 | 11 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2020 | 190 | 0.140 |
Why?
|
| Lymphoma | 1 | 2017 | 6 | 0.140 |
Why?
|
| Bone Density | 3 | 2007 | 94 | 0.140 |
Why?
|
| Datasets as Topic | 1 | 2017 | 20 | 0.140 |
Why?
|
| Biopsy | 3 | 2009 | 82 | 0.140 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 56 | 0.140 |
Why?
|
| Blood Pressure | 1 | 2019 | 275 | 0.140 |
Why?
|
| African Continental Ancestry Group | 3 | 2017 | 144 | 0.140 |
Why?
|
| Bias | 3 | 2023 | 100 | 0.140 |
Why?
|
| Sigmoidoscopy | 2 | 2007 | 65 | 0.140 |
Why?
|
| Databases, Factual | 4 | 2017 | 306 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 9 | 0.140 |
Why?
|
| Rosacea | 2 | 2007 | 3 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 45 | 0.140 |
Why?
|
| Social Class | 1 | 2017 | 117 | 0.140 |
Why?
|
| Acne Vulgaris | 2 | 2007 | 8 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2017 | 24 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2022 | 44 | 0.130 |
Why?
|
| Washington | 5 | 1998 | 385 | 0.130 |
Why?
|
| Diabetes Mellitus | 3 | 2010 | 455 | 0.130 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2016 | 2 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 15 | 0.130 |
Why?
|
| Research Design | 3 | 2015 | 343 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 10 | 0.130 |
Why?
|
| Child Health | 1 | 2017 | 39 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2017 | 54 | 0.130 |
Why?
|
| Pregnancy | 5 | 2010 | 1466 | 0.130 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 14 | 0.130 |
Why?
|
| Research | 1 | 2017 | 61 | 0.130 |
Why?
|
| Causality | 1 | 2016 | 36 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 342 | 0.130 |
Why?
|
| Child Development | 1 | 2017 | 53 | 0.130 |
Why?
|
| Tumor Burden | 2 | 2013 | 19 | 0.130 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 23 | 0.130 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2017 | 216 | 0.130 |
Why?
|
| Contraceptives, Oral | 1 | 1996 | 25 | 0.130 |
Why?
|
| Metabolic Equivalent | 1 | 2016 | 8 | 0.130 |
Why?
|
| Breast Feeding | 2 | 2015 | 113 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 13 | 0.130 |
Why?
|
| Motor Activity | 2 | 2015 | 208 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 52 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 84 | 0.120 |
Why?
|
| Anthracyclines | 2 | 2012 | 14 | 0.120 |
Why?
|
| Nomograms | 1 | 2015 | 12 | 0.120 |
Why?
|
| Obesity | 2 | 2015 | 814 | 0.120 |
Why?
|
| Pathology Department, Hospital | 1 | 2015 | 3 | 0.120 |
Why?
|
| Women, Working | 1 | 1995 | 6 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2016 | 64 | 0.120 |
Why?
|
| Estrogens | 3 | 2010 | 60 | 0.120 |
Why?
|
| Occupational Diseases | 1 | 1995 | 38 | 0.120 |
Why?
|
| Inflammation | 1 | 2015 | 63 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 9 | 0.110 |
Why?
|
| Proteinuria | 1 | 2014 | 25 | 0.110 |
Why?
|
| Insurance Claim Review | 1 | 2014 | 55 | 0.110 |
Why?
|
| Insulin Glargine | 1 | 2013 | 8 | 0.110 |
Why?
|
| Reference Values | 2 | 2012 | 86 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2014 | 24 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 10 | 0.100 |
Why?
|
| Stroke | 2 | 2016 | 310 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 9 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 380 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2015 | 253 | 0.100 |
Why?
|
| Hormones | 2 | 2015 | 14 | 0.100 |
Why?
|
| Estradiol | 2 | 2015 | 23 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2012 | 180 | 0.100 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2011 | 4 | 0.090 |
Why?
|
| Amines | 1 | 2011 | 5 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 5 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2011 | 9 | 0.090 |
Why?
|
| Phenotype | 2 | 2022 | 148 | 0.090 |
Why?
|
| Iron | 2 | 2008 | 16 | 0.090 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 32 | 0.090 |
Why?
|
| Menstruation | 1 | 2011 | 7 | 0.090 |
Why?
|
| Sulfonylurea Compounds | 2 | 2010 | 25 | 0.090 |
Why?
|
| Densitometry | 1 | 2011 | 1 | 0.090 |
Why?
|
| Prazosin | 1 | 2011 | 1 | 0.090 |
Why?
|
| Clonidine | 1 | 2011 | 3 | 0.090 |
Why?
|
| Propranolol | 1 | 2011 | 4 | 0.090 |
Why?
|
| Atenolol | 1 | 2011 | 6 | 0.090 |
Why?
|
| Metoprolol | 1 | 2011 | 6 | 0.090 |
Why?
|
| Perimenopause | 2 | 2009 | 11 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 53 | 0.090 |
Why?
|
| Adipose Tissue | 2 | 2009 | 65 | 0.090 |
Why?
|
| Health Services Research | 1 | 2012 | 212 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2011 | 84 | 0.090 |
Why?
|
| Vitamins | 1 | 2011 | 59 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2010 | 3 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2010 | 12 | 0.090 |
Why?
|
| Insulin | 2 | 2010 | 190 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2010 | 26 | 0.090 |
Why?
|
| Laboratories | 1 | 2010 | 19 | 0.090 |
Why?
|
| Age of Onset | 2 | 2007 | 70 | 0.080 |
Why?
|
| Medical Audit | 1 | 2010 | 36 | 0.080 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 3 | 0.080 |
Why?
|
| Massachusetts | 1 | 2010 | 67 | 0.080 |
Why?
|
| Fetus | 1 | 1990 | 5 | 0.080 |
Why?
|
| Narcotics | 1 | 1990 | 6 | 0.080 |
Why?
|
| Carcinogenicity Tests | 1 | 2009 | 2 | 0.080 |
Why?
|
| Carcinogens | 1 | 2009 | 3 | 0.080 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1990 | 13 | 0.080 |
Why?
|
| Infant Mortality | 1 | 1990 | 15 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2010 | 106 | 0.080 |
Why?
|
| Glycated Hemoglobin A | 1 | 2010 | 184 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 225 | 0.080 |
Why?
|
| Adenoma | 1 | 2010 | 95 | 0.080 |
Why?
|
| Substance-Related Disorders | 2 | 1993 | 424 | 0.080 |
Why?
|
| Ferritins | 1 | 2008 | 8 | 0.080 |
Why?
|
| Ligands | 1 | 2008 | 6 | 0.080 |
Why?
|
| Antiprotozoal Agents | 1 | 2008 | 2 | 0.080 |
Why?
|
| Griseofulvin | 1 | 2008 | 2 | 0.080 |
Why?
|
| Metronidazole | 1 | 2008 | 4 | 0.080 |
Why?
|
| Furosemide | 1 | 2008 | 3 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2008 | 4 | 0.070 |
Why?
|
| Hemochromatosis | 1 | 2008 | 7 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 7 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 395 | 0.070 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 8 | 0.070 |
Why?
|
| Pennsylvania | 1 | 2008 | 26 | 0.070 |
Why?
|
| Glycemic Index | 1 | 2008 | 19 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2008 | 38 | 0.070 |
Why?
|
| Lovastatin | 1 | 2008 | 7 | 0.070 |
Why?
|
| Genomics | 2 | 2020 | 56 | 0.070 |
Why?
|
| Amphetamines | 1 | 2007 | 2 | 0.070 |
Why?
|
| Leukemia, Lymphoid | 1 | 2007 | 2 | 0.070 |
Why?
|
| Pemoline | 1 | 2007 | 2 | 0.070 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2007 | 10 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 316 | 0.070 |
Why?
|
| Simvastatin | 1 | 2008 | 11 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2007 | 12 | 0.070 |
Why?
|
| Insurance Carriers | 1 | 2007 | 6 | 0.070 |
Why?
|
| Ibuprofen | 1 | 2007 | 9 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2009 | 278 | 0.070 |
Why?
|
| Tetracyclines | 1 | 2006 | 2 | 0.070 |
Why?
|
| Macrolides | 1 | 2006 | 6 | 0.070 |
Why?
|
| Risk Adjustment | 1 | 2006 | 20 | 0.070 |
Why?
|
| Prepaid Health Plans | 1 | 2006 | 19 | 0.060 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2006 | 3 | 0.060 |
Why?
|
| Survivors | 3 | 2015 | 157 | 0.060 |
Why?
|
| Deductibles and Coinsurance | 1 | 2006 | 31 | 0.060 |
Why?
|
| Alleles | 2 | 2017 | 80 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2004 | 40 | 0.060 |
Why?
|
| Weight Gain | 1 | 2006 | 156 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 19 | 0.060 |
Why?
|
| Glioma | 1 | 2004 | 4 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 13 | 0.060 |
Why?
|
| Health Status | 1 | 2006 | 295 | 0.060 |
Why?
|
| Body Size | 1 | 2024 | 31 | 0.060 |
Why?
|
| Health Behavior | 1 | 2006 | 345 | 0.050 |
Why?
|
| International Cooperation | 2 | 2015 | 15 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 366 | 0.050 |
Why?
|
| Mastectomy | 1 | 2023 | 37 | 0.050 |
Why?
|
| HIV Infections | 1 | 2009 | 712 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 24 | 0.050 |
Why?
|
| Whole Exome Sequencing | 1 | 2022 | 8 | 0.050 |
Why?
|
| Exome | 1 | 2022 | 21 | 0.050 |
Why?
|
| Vaccination | 2 | 2024 | 685 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 2 | 2012 | 81 | 0.050 |
Why?
|
| Hispanic Americans | 2 | 2015 | 378 | 0.050 |
Why?
|
| Sudden Infant Death | 2 | 1993 | 10 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2005 | 273 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 58 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2012 | 203 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 29 | 0.040 |
Why?
|
| Observer Variation | 1 | 2001 | 36 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2001 | 29 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 57 | 0.040 |
Why?
|
| Genetic Pleiotropy | 1 | 2020 | 9 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 223 | 0.040 |
Why?
|
| Body Height | 1 | 2000 | 60 | 0.040 |
Why?
|
| Diet | 2 | 2010 | 356 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 285 | 0.040 |
Why?
|
| Sex Factors | 3 | 2010 | 607 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 53 | 0.040 |
Why?
|
| San Francisco | 1 | 1999 | 59 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1990 | 63 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 1999 | 72 | 0.040 |
Why?
|
| Genital Diseases, Male | 1 | 1998 | 2 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2008 | 142 | 0.030 |
Why?
|
| Oncologists | 1 | 2017 | 7 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 39 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 23 | 0.030 |
Why?
|
| Prostate | 1 | 2017 | 28 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 59 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 108 | 0.030 |
Why?
|
| Body Weight | 2 | 2009 | 203 | 0.030 |
Why?
|
| Multigene Family | 1 | 2016 | 6 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2016 | 1 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 1 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 211 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 2016 | 18 | 0.030 |
Why?
|
| Drug Approval | 1 | 2016 | 12 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2016 | 31 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 83 | 0.030 |
Why?
|
| Health Resources | 1 | 2015 | 34 | 0.030 |
Why?
|
| Capsid | 1 | 1995 | 1 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Progestins | 1 | 1995 | 25 | 0.030 |
Why?
|
| Androgens | 1 | 2015 | 14 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 19 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 38 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 112 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 15 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 18 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 34 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 1995 | 61 | 0.030 |
Why?
|
| Tobacco | 1 | 2014 | 11 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2016 | 152 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 145 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 3 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2014 | 11 | 0.030 |
Why?
|
| Utah | 1 | 2014 | 32 | 0.030 |
Why?
|
| New York City | 2 | 1993 | 24 | 0.030 |
Why?
|
| Heroin | 1 | 1993 | 5 | 0.030 |
Why?
|
| Methadone | 1 | 1993 | 10 | 0.030 |
Why?
|
| Cocaine | 1 | 1993 | 7 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2014 | 104 | 0.030 |
Why?
|
| Taxoids | 1 | 2012 | 8 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 30 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 7 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 73 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 25 | 0.020 |
Why?
|
| Health Personnel | 1 | 2012 | 126 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1993 | 168 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 1993 | 805 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 178 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 120 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2012 | 148 | 0.020 |
Why?
|
| Self Report | 1 | 2012 | 257 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Incretins | 1 | 2010 | 2 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2010 | 6 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2010 | 8 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 311 | 0.020 |
Why?
|
| Testosterone | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cytokines | 1 | 2010 | 30 | 0.020 |
Why?
|
| Factor VIII | 1 | 1990 | 1 | 0.020 |
Why?
|
| Transfusion Reaction | 1 | 1990 | 2 | 0.020 |
Why?
|
| Factor IX | 1 | 1990 | 3 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 205 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2009 | 2 | 0.020 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2009 | 3 | 0.020 |
Why?
|
| HIV-1 | 1 | 1990 | 71 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 5 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Aromatase | 1 | 2009 | 9 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 10 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2009 | 7 | 0.020 |
Why?
|
| Cause of Death | 1 | 1990 | 175 | 0.020 |
Why?
|
| Iron, Dietary | 1 | 2008 | 8 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2008 | 19 | 0.020 |
Why?
|
| Hemochromatosis Protein | 1 | 2008 | 7 | 0.020 |
Why?
|
| Homozygote | 1 | 2008 | 13 | 0.020 |
Why?
|
| Heterozygote | 1 | 2008 | 26 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2008 | 6 | 0.020 |
Why?
|
| Overweight | 1 | 2010 | 266 | 0.020 |
Why?
|
| Men's Health | 1 | 2007 | 20 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2007 | 33 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 100 | 0.020 |
Why?
|
| Fertility Agents, Female | 1 | 2007 | 2 | 0.020 |
Why?
|
| Hip | 1 | 2007 | 9 | 0.020 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2007 | 12 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 19 | 0.020 |
Why?
|
| Thigh | 1 | 2007 | 11 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 23 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2007 | 12 | 0.020 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2007 | 42 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2007 | 31 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2007 | 48 | 0.020 |
Why?
|
| Muscle Relaxation | 1 | 2006 | 3 | 0.020 |
Why?
|
| Xanthines | 1 | 2006 | 6 | 0.020 |
Why?
|
| Nitrates | 1 | 2006 | 9 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2006 | 33 | 0.020 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2006 | 86 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2006 | 103 | 0.020 |
Why?
|
| Health Surveys | 1 | 2006 | 250 | 0.020 |
Why?
|
| Rubella Vaccine | 1 | 1985 | 9 | 0.020 |
Why?
|
| Endoscopy, Digestive System | 1 | 2002 | 10 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1995 | 1 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1995 | 2 | 0.010 |
Why?
|
| DNA Primers | 1 | 1995 | 8 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 14 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 18 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 17 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1995 | 107 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1994 | 18 | 0.010 |
Why?
|
| Vitamin A | 1 | 1994 | 14 | 0.010 |
Why?
|
| Urban Population | 1 | 1993 | 109 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1990 | 8 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1990 | 31 | 0.010 |
Why?
|
| Infant | 1 | 1993 | 1162 | 0.010 |
Why?
|
| Rubella | 1 | 1985 | 7 | 0.000 |
Why?
|
| Disease Outbreaks | 1 | 1985 | 37 | 0.000 |
Why?
|
| Immunization | 1 | 1985 | 69 | 0.000 |
Why?
|